Pembrolizumab Plus Olaparib in LA-HNSCC

NCT05366166 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Olaparib
DRUG: Cisplatin
RADIATION: IMRT (intensity modulated radiation therapy)

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]